A recent clinical trial conducted in South San Francisco revealed promising results regarding the supplementation of Brightseed® BioMetaControl. The trial, which was randomized, double-blind, and placebo-controlled, demonstrated significant improvements in markers of glycemic control among adults with prediabetes. This supplement contains the natural bioactive compounds N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT). The study's findings were published in the reputable journal Bioactive Compounds in Health and Disease. Further research indicated the positive impact of this supplementation in managing prediabetes in adults.